[Use of ursodeoxycholic acid combined with silymarin in the treatment of chronic ethyl-toxic hepatopathy].
30 patients, affected by chronic ethylic hepatopathy, were treated with 450 mg/daily of ursodeoxycholic acid (UDCA): after six months, a significant decrease of serum hepatic enzymes was noted. The addition of silymarin (400 mg/daily) to UDCA in other 30 patients, induced a further improvement of hepatic function.
Bettini
R
R
Ospedale di Circolo, Università degli Studi dell'Insubria, Varese, Italia.
Gorini
M
M
D000328:Adult; D000368:Aged; D000975:Antioxidants / Q000627:therapeutic use*; D002756:Cholagogues and Choleretics / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D006519:Hepatitis, Alcoholic / Q000188:drug therapy* / Q000201:enzymology; D006801:Humans; D008099:Liver / Q000201:enzymology; D008297:Male; D008875:Middle Aged; D020011:Protective Agents / Q000627:therapeutic use*; D012838:Silymarin / Q000627:therapeutic use*; D016896:Treatment Outcome; D014580:Ursodeoxycholic Acid / Q000627:therapeutic use*
D000975:Antioxidants; D002756:Cholagogues and Choleretics; D020011:Protective Agents; D012838:Silymarin; D014580:Ursodeoxycholic Acid